This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
LabCorp (LH) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of -4.53% and -0.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Q3 Earnings on Oct 24: BSX, ALGN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry appears promising at the moment amid certain short-term geopolitical insecurities.
LabCorp (LH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.
LabCorp (LH) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics Buys PhenoPath, Grows in Anatomic Pathology
by Zacks Equity Research
With the rising need for AP and molecular oncology services in healthcare, we consider the acquisition of PhenoPath by Quest Diagnostics (DGX) to be well-timed and a strategic fit for its portfolio.
Will LabCorp's (LH) Food Solution Divestment Upset Sales?
by Zacks Equity Research
LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.
Medical Services Boom Drives Healthcare: 3 Top Picks
by Sreyoshi Mukherjee
Considering the rising popularity of PBM, CRO and EHR in the U.S. Medical Services industry, these three picks might be money-spinning choices for investors.
Why Is LabCorp (LH) Up 0.8% Since Last Earnings Report?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.
LabCorp (LH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 2.05% and 0.59%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?